CA-THERMO-FISHER
29.3.2023 14:01:30 CEST | Business Wire | Press release
Thermo Fisher Scientific, the world leader in serving science, and Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage cell therapy company engineering advanced chimeric antigen receptor (CAR)-T cell therapies for solid tumors, today announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments. This research and process development-focused collaboration has enabled ArsenalBio to develop a robust manufacturing process for their next-generation, programmable autologous T cells for the treatment of cancer.
ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for platinum-resistant ovarian cancer. ArsenalBio’s work to develop multi-functional CAR-T cell therapies is enabled by Thermo Fisher’s Cell Therapy Systems (CTS) portfolio of products, including the Gibco™ CTS™ Xenon™ Electroporation System and the Gibco™ CTS™ Rotea™ Counterflow Centrifugation System.
“Our programmable cell therapy technology holds the potential to help patients with aggressive and complex cancers who currently have few treatment options,” said Ken Drazan, M.D., co-founder and chief executive officer, ArsenalBio. “To bring the promise of this technology to patients we’ll need to execute at speed and scale as we transition to clinical development. Our relationship with Thermo Fisher allows us to combine their fit-for-purpose solutions and internal expertise with our team’s innovative approach to clinical research and process development capabilities to manufacture ArsenalBio’s products and explore future therapeutic innovation.”
Thermo Fisher began its collaboration with ArsenalBio in 2020 to help ArsenalBio overcome challenges associated with cell therapy manufacturing by working together to support development of a clinical-scale gene editing process. In addition, ArsenalBio received early access to Thermo Fisher’s latest instrumentation and reagents.
“By collaborating with ArsenalBio as they pioneer a new approach to treat solid tumors using engineered T cell therapies, we’re helping bring more options to those who are most in need of innovative treatments,” said Betty Woo, vice president of cell, gene and advanced therapies, Thermo Fisher. “Through our Cell Therapy Collaboration Program, we are enabling the industry shift from reactive to proactive, applying our biological and technical expertise to improve the economics of therapy production, and moving toward expanded access to patients worldwide.”
Thermo Fisher’s CTS portfolio of products are cGMP manufactured, designed to meet applicable cell therapy standards, and include traceability and regulatory documentation to help customers transition from research to clinical production.
For more information about Thermo Fisher’s cell therapy collaboration partnership program, please visit thermofisher.com/collabcenterpartnership.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005043/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
70% of Enterprise AI is Uncontrolled, Driving Hidden Risk, Cost and Slower ROI27.4.2026 10:00:00 CEST | Press release
Lenovo research highlights a growing AI execution gap as organizations struggle to control and operate AI across their environments AI is already being used across your organization, whether it has been formally approved or not. Employees are using AI with or without IT involvement, fueling the rise of ‘shadow AI’ across the enterprise, creating gaps in governance and control. This is no longer just an IT challenge. For Chief Information Security Officers, this shift is expanding the attack surface across devices, endpoints, and data flows, introducing unmanaged risk and increasing the likelihood of sensitive company data being exposed or accessed without proper controls. What this reveals is a growing AI execution gap: usage is accelerating, but control is not keeping pace. Based on a survey of 6,000 employees worldwide, Lenovo’s latest Work Reborn Report, Leading Your Workforce to Triumph with AI, finds that more than 70% of employees are using AI weekly, with up to one third operati
First Enterprise Quantum Computer Purchase in Japan: IQM to Deploy System to TOYO Corporation27.4.2026 08:00:00 CEST | Press release
First enterprise quantum computer purchase in Japan cements IQM's position as the global leader in deployed quantum computers The Radiance 20-qubit system will enable TOYO to explore various industry use cases, while advancing a hybrid quantum-HPC infrastructure. This will be the third quantum computer to be deployed by IQM in the Asia-Pacific region. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the purchase of its full-stack 20-qubit quantum computer by TOYO Corporation, marking the first enterprise quantum system deployment in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426053944/en/ (From Left): Toshiya Kohno, Representative Director, President and CEO of TOYO Corporation, and Jan Goetz, CEO & Co-founder of IQM Quantum Computers. The Radiance 20-qubit system will be made available in both on-premises and cloud environments and will be delivered by the end of 2
SAP and S3NS Accelerate Trusted Cloud Adoption in France With Thales as First Strategic Customer27.4.2026 08:00:00 CEST | Press release
Thales adopts SAP RISE private cloud edition on S3NS to transform its ERP (Enterprise Resource Planning) landscape and operationalize digital sovereignty at scale. By combining SAP’s enterprise applications and Business AI capabilities with S3NS’s trusted infrastructure, this partnership unlocks cloud adoption for highly regulated sectors, including public administration, aerospace and defense, and operators of vital and essential services. Thales (Euronext Paris: HO): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426644177/en/ Strategic partnership (c)S3NS A decisive step in scaling trusted cloud in Europe The strategic partnership between SAP and S3NS, the trusted cloud provider established by Thales and Google Cloud, will strengthen trusted cloud capabilities in France and support Europe’s growing demand for cloud business transformation. SAP RISE private cloud edition will be deployed by SAP Sovereign Cloud on S3NS’
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom